Pantogam, tablets 250 mg 50 pcs

The spectrum of action of Pantogam® is due to the presence of gamma-aminobutyric acid (GABA) in its structure. The mechanism of action is due to the direct effect of the drug on the GABA-receptor-channel complex.

It has nootropic and anticonvulsant effect. It increases resistance of the brain to hypoxia and toxic substances, stimulates anabolic processes in neurons, combines moderate sedative action with a mild stimulating effect, reduces motor excitability and activates mental and physical performance.

It improves GABA metabolism in chronic alcohol intoxication and after withdrawal of ethanol.

It is able to inhibit acetylation reactions participating in inactivation mechanisms of procaine and sulfonamides and due to this prolongation of their action is achieved. It causes inhibition of pathologically increased bladder reflex and detrusor tone.

Pharmacokinetics

Pantogam® is quickly absorbed from the gastrointestinal tract, passes through the BBB, the highest concentrations are formed in the liver, kidneys, stomach wall and skin. It is not metabolized and excreted unchanged within 48 hours: 67.5% of the administered dose is excreted in the urine, 28.5% – in the faeces.

Indications

cognitive impairment in organic brain lesions (including consequences of neuroinfections and head injury) and neurotic disorders;
schizophrenia with cerebral organic failure;
cerebrovascular insufficiency caused by atherosclerotic changes in cerebral vessels;
extrapyramidal disorders (myoclonus epilepsy, Huntington’s chorea, hepatolenticular degeneration, Parkinson’s disease, etc.);
treatment and prevention of extrapyramidal syndrome (hyperkinetic and akinetic) caused by taking antipsychotics;
epilepsy with slow mental processes in complex therapy with anticonvulsants;
psycho-emotional overload;
decreased mental and physical performance, to improve concentration and memory;
neurogenic urinary disorders (pollakiuria, urgency, imperative urinary incontinence, enuresis).
in children with perinatal encephalopathy;
mental retardation of varying severity in children;
developmental delay (mental, speech, motor or a combination thereof) in children;
various forms of cerebral palsy;
hyperkinetic disorders (attention deficit hyperactivity disorder) in children;
neurosis-like states (with stuttering, mainly in clonic form, tics) in children.

Pharmacological effect

The spectrum of action of Pantogam® is associated with the presence of gamma-aminobutyric acid (GABA) in its structure. The mechanism of action is due to the direct effect of the drug on the GABAB receptor-channel complex.

Has nootropic and anticonvulsant effects. Increases the brain’s resistance to hypoxia and the effects of toxic substances, stimulates anabolic processes in neurons, combines a moderate sedative effect with a mild stimulating effect, reduces motor excitability, and activates mental and physical performance.

Improves GABA metabolism during chronic alcohol intoxication and after ethanol withdrawal.

It is capable of inhibiting acetylation reactions involved in the mechanisms of inactivation of procaine (novocaine) and sulfonamides, thereby prolonging the action of the latter. Causes inhibition of the pathologically increased bladder reflex and detrusor tone.

Pharmacokinetics

Pantogam® is quickly absorbed from the gastrointestinal tract, passes through the blood-brain barrier, the highest concentrations are created in the liver, kidneys, stomach wall and skin. It is not metabolized and is excreted unchanged within 48 hours: 67.5% of the dose taken is excreted in the urine, 28.5% in feces.

Special instructions

If allergic reactions develop, the drug should be discontinued.

During long-term treatment, simultaneous administration of Pantogam with other nootropic drugs and central nervous system stimulants is not recommended.

Active ingredient

Hopantenic acid

Composition

Active ingredient:

calcium hopanthenate (Pantogam®) 250 and 500 mg;

Excipients:

methylcellulose,

calcium stearate,

magnesium hydroxycarbonate,

talc

Contraindications

hypersensitivity;
acute severe kidney disease;
pregnancy (first trimester – syrup);
pregnancy (pills);
phenylketonuria (syrup, contains aspartame)
breastfeeding period (tablets).
children under 3 years of age (tablets).

Side Effects

Allergic reactions: possible rhinitis, conjunctivitis, skin rashes.

Other: possible sleep disturbances or drowsiness, tinnitus (these symptoms are usually short-lived and do not require discontinuation of the drug).

Interaction

Prolongs the effect of barbiturates, enhances the effect of anticonvulsants, prevents the side effects of phenobarbital, carbamazepine, and neuroleptics.

Potentiates the effect of local anesthetics (procaine).

The effect of Pantogam® is enhanced in combination with glycine and etidronic acid (xidifon).

Overdose

Symptoms: increased symptoms of side effects (sleep disturbance or drowsiness, noise in the head).

Treatment: administration of activated carbon, gastric lavage, symptomatic therapy.

Storage conditions

The drug should be stored in a place protected from light at a temperature of 15° to 20°C.

Shelf life

3 years

Manufacturer

Peak-Pharma Lek, Russia